VERTEX PHARMACEUTICALS Aktie

 

Die Übernahmewelle im Biotechnologiesektor rollt mit unverminderter Dynamik weiter. Mit der angekündigten Übernahme von Crinetics Pharmaceuticals für rund 10 Milliarden US-Dollar setzt Vertex Pharmaceuticals ein deutliches Zeichen im Wettbewerb um innovative Medikamentenentwickler. Der Konzern ist bereit, für das Biotech-Unternehmen einen außergewöhnlich hohen Aufschlag zu zahlen – ein klares Signal dafür, wie begehrt aussichtsreiche Wirkstoffpipelines derzeit […] The post Crinetics Pharmaceuticals +100%: Biotech-Übernahmewelle heftiger denn je! first appeared on sharedeals.de....

Eine Milliardenübernahme bewegt den Biotechsektor: Vertex Pharmaceuticals übernimmt Crinetics Pharmaceuticals und sorgt für massive Kursbewegungen....

Der Biopharma-Riese Vertex Pharmaceuticals ist weltweit für seine unangefochtene Marktführerschaft bei Mukoviszidose-Medikamenten bekannt. Doch das Unternehmen will sich von dem margenstarken Geschäft unabhängiger machen. Mit der größten Übernahme in der Firmengeschichte soll der nächste Diversifizierungsschritt erfolgen....

Liu, Joy - Vorstand - Tag der Transaktion: 2026-07-01...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said....

CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals (VRTX) said Monday it has agreed to acquire Crinetics Pharmaceuticals (CRNX) in an all-cash deal valued at approximately $10 billion, s......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Vertex Pharmaceuticals Inc. agreed to buy Crinetics Pharmaceuticals Inc. for $10 billion in cash to expand into endocrinology, including medicines for acromegaly and hormone disorders....

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - - PALSONIFY®, Crinetics' recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing's syndrome - - Acquisition adds to Vertex's innovation pipeline, accelerates Vertex's revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET -BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporate...

The pharma stock is up around 17% this year....

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders....

BASEL (dpa-AFX) - The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readout......

BASEL (dpa-AFX) - The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readout......

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?...

Bozic, Carmen - Vorstand - Tag der Transaktion: 2026-06-26...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles....

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $475.12, indicating a +1.43% shift from the previous trading day....

Bozic, Carmen - Vorstand - Tag der Transaktion: 2026-06-18...